VSports app下载 - Clinical Domain Working Groups

The World Health Organization (WHO) recently designated BCR::ABL1-like B-ALL as an entity within the 5th edition of the Classification of Haematolymphoid Tumours and acknowledged its genetic heterogeneity (PMID: 35732829) VSports. Moreover, the Internal Consensus Committee (ICC) has divided BCR::ABL1-like B-ALL into three subgroups: ABL- class rearranged, JAK/STAT activated, and not otherwise specified (PMID: 35767897). In keeping with the recommendations of the CDWG Oversight Committee, the SC-VCEP will therefore evaluate genetic alterations described in each of these disease subgroups and recognized in the medical literature, as well as by the WHO and ICC, as being implicated in pathogenesis of BCR::ABL1-like B-ALL. Specifically, ABL-class gene rearrangements of ABL1, ABL2, CSF1R, PDGFRA, and PDGFRB shall be examined, as well as rearrangements of CRLF2, JAK2, EPOR, TSLP, and IL2RB, and point mutations of JAK2, IL7R, SH2B3, JAK1, JAK3, TSLP, and IL2RB, which are implicated in JAK/STAT signaling. Additional rearrangements of DGKH, PTK2B, LYN, TYK2, and BLNK will also be considered, but those involving FLT3, NTRK3, and FGFR1 shall be reserved for the discussions of SC-VCEPs focused on those genes.